Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro

Cancer Biology and Therapy

Volumn 11, Issue 12, 2011, Pages 1036-1045

  Singh, Rakesh K ^a   Dorf, Lee ^b   DeMartino, Angelica ^a   Illenye, Sharon ^b   Koto, Karen ^b   Currier, Erika A ^b   Ashikaga, Takamaru ^b   Kim, Kyu Kwang ^a   Brard, Laurent ^c   Saulnier Sholler, Giselle L ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Medulloblastoma; Neuroblastoma; Nifurtimox; RKS262; ROS; SAPK JNK; Xenograft

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CYCLIN B1; CYCLIN D1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NIFURTIMOX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RKS 262; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NICK END LABELING; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; CYCLIC S-OXIDES; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, NUDE; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958831630     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.12.15706     Document Type: Article

References (43)

1. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993; 11:1466-77. (Pubitemid 23228250)
2. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology and survival. J Pediatr Hematol Oncol 1999; 21:181-9. (Pubitemid 30306028)
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nature Reviews 2003; 3:203-16. (Pubitemid 37328872)
4. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol 2009; 27:365-70.
5. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455:971-4.
6. Middlemas DS, Kihl BK, Zhou J, Zhu X. Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J Biol Chem 1999; 274:16451-60.
7. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol-3′-kinase pathway. Cancer Res 2002; 62:6756-63. (Pubitemid 35364148)
8. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 2006; 66:4249-55.
9. Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005; 65:9868-75. (Pubitemid 41541466)
10. Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998; 58:5432-8. (Pubitemid 28551127)
11. Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A, et al. Targeting the phosphoinositide- 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008; 14:1172-81. (Pubitemid 351302566)
12. Svensson K, Zeidman R, Troller U, Schultz A, Larsson C. Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation. Cell Growth Differ 2000; 11:641-8. (Pubitemid 32042987)
13. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009; 69:329-37.
14. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006; 439:95-9. (Pubitemid 43053635)
15. Niizuma H, Nakamura Y, Ozaki T, Nakanishi H, Ohira M, Isogai E, et al. Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 2006; 25:5046-55.
16. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. Children's Cancer Group. New Engl J Med 1999; 341:1165-73. (Pubitemid 29480654)
17. Simon T, Langler A, Harnischmacher U, Fruhwald MC, Jorch N, Claviez A, et al. Topotecan, cyclophosphamide and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Canc Res Clin 2007; 133:653-61. (Pubitemid 47077057)
18. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma. New Engl J Med 2010; 363:1324-34.
19. Marengo B, Raffaghello L, Pistoia V, Cottalasso D, Pronzato MA, Marinari UM, et al. Reactive oxygen species: biological stimuli of neuroblastoma cell response. Cancer Lett 2005; 228:111-6. (Pubitemid 41188432)
20. Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA, et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 1999; 5:3594-602.
21. Saulnier Sholler GL, Kalkunte S, Greenlaw C, McCarten K, Forman E. Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J Pediatr Hematol Oncol 2006; 28:693-5. (Pubitemid 44536052)
22. Saulnier Sholler GL, Brard L, Straub JA, Dorf L, Illeyne S, Koto K, et al. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J Pediatr Hematol Oncol 2009; 31:187-93.
23. Saulnier Sholler GL. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol 2011; 33:25-30.
24. Saulnier Sholler GLSH, Kalkunte S, Singh RK, Brard LKK. Nitrofuran compounds for the treatment for the treatment of cancer and angiogenesis. In: WIPO, ed. 2007.
25. Singh RK, Lange TS, Kim KK, Brard L. A coumarin derivative (RKS262) inhibits cell cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells. Invest New Drugs 2009; 29:63-72.
26. Brard L SR, Kim KK, Saulnier Sholler G. N-aminotetrahydrothiazine derivatives, method of manufacture and use. PCT application WO/2008/091946 2008.
27. Acosta S, Lavarino C, Paris R, Garcia I, de Torres C, Rodriguez E, et al. Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells. BMC Dev Biol 2009; 9:12.
28. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58:5396-405. (Pubitemid 28551122)
29. Carlson K, Ehrich M. Organophosphorus compound-induced modification of SH-SY5Y human neuroblastoma mitochondrial transmembrane potential. Toxicol Appl Pharmacol 1999; 160:33-42.
30. Thornberry NA, Lazebnik Y. Caspases: Enemies Within. Science 1998; 281:1312-6. (Pubitemid 28406817)
31. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992; 356:356-8.
32. Sholler GS. Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma 2008.
33. Paull MBaK. Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev Res 1995; 34:91-109.
34. Cuperus R, Tytgat GA, Leen R, Brites P, Bras J, Caron HN, et al. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. Int J Oncol 2008; 32:1011-9.
35. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev 2008; 7:989-1000.
36. Dole MG Jr, Cooper MJ, Thompson CB, Nuñez G, Castle VP. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55:2576-82.
37. Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Canc Biol Ther 2009; 8:1587-95.
38. Norbury, C. J. The cancer cell cycle. In: M. Knowles and P. Selby, eds. Cellular and molecular biology of cancer. 4th. Oxford University Press, 2005:156-169.
39. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
40. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008; 68:2599-609. (Pubitemid 351556258)
41. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle check point function. Free Radic Biol Med 2000; 28:1387-404. (Pubitemid 30621482)
42. Ambrosino C, Nebreda AR. Cell cycle regulation by p38 MAPKs. Biol Cell 2001; 93:47-51. (Pubitemid 33040859)
43. Wang XM, Terasaki PI, Rankin GW Jr, Chia D, Zhong HP, Hardy S. A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol 1993; 37:264-70. (Pubitemid 23343716)